Zytiga® (abiraterone acetate) survival data in chemotherapy-naïve men with metastatic castration resistant prostate cancer (mCRPC) revealed

Data from the final analysis of the Phase 3 study COU-AA-302 have shown that Zytiga® (abiraterone acetate) plus low dose prednisolone significantly prolongs overall survival (OS) with a median...